Episode 60: Riociguat in patients with PAH and Cardiometabolic Comorbidities
Release Date: 03/18/2025
Episode 62: Apixaban Plasma Levels in Patients with HeartMate 3
JHLT: The Podcast
Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, “.” As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom’s work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support. The episode explores: The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors Encouraging findings from the study and what...
info_outline
Episode 61: Is Sotatercept safe in patients with PAH?
JHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite author Ioana Preston, MD, to discuss the paper, “.” Dr. Preston is the director of the pulmonary hypertension center at Lahey Hospital and Medical Center in Burlington, Massachusetts, and has over 20 years of experience in caring for patients with PH, as well as multiple clinical trials in PH. The episode explores: What makes sotatercept unique as the first “biologic” in the treatment of PAH Hypotheses about the mechanism of action in sotatercept Sotatercept’s interaction with mPAP and what it...
info_outline
Episode 60: Riociguat in patients with PAH and Cardiometabolic Comorbidities
JHLT: The Podcast
Returning for a second study this month, the JHLT Digital Media Editors conduct an internal discussion on the paper, “.” The episode explores: The aging PAH population and the new comorbidities that must be considered in research How the study augments and expands on recent standards, like the 2022 ESC/ERS guidelines for pulmonary hypertension Limitations on the study and opportunities for future research For the latest studies from JHLT, visit , or, if you’re an ISHLT member, access your Journal membership at . Those on lung transplant teams should check the previous...
info_outline
Episode 59: Rewarming Ischemia Time in Lung Transplantation
JHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Jan Van Slambrouck, MD, to discuss the paper, “.” Dr. Van Slambrouck is a general surgeon who’s just finished his PhD training at the KU Leuven lab of respiratory disease and thoracic surgery in Belgium. The episode explores: How rewarming ischemia time (RIT) affects donor lungs, especially on the molecular level The pace of rewarming and how prior literature prepared the team to track and evaluate it Clinical strategies to reduce RIT and directly address molecular changes For...
info_outline
Episode 58: Sympathetic Reinnervation
JHLT: The Podcast
Returning for a second study this month, the JHLT Digital Media Editors invite lead author Oliver J.F. Weiner, to discuss the paper, “.” Dr. Weiner is currently an out of training registrar at Monash Health in Melbourne, Australia, but will soon return to his home of the UK to begin internal medicine training with the intention becoming a cardiologist. He is especially interested in advanced heart failure and electrophysiology. The episode explores: The uncertainty around clinical influences on reinnervation The importance of this single-center study in expanding the literature Potential...
info_outline
Episode 57: Trends and Outcomes in EVLP
JHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Jonathan E. Williams, MD, to discuss the paper, “.” Dr. Williams is a general surgery resident at the University of Michigan in Ann Arbor, with work focusing on contemporary lung preservation strategies, perfusion techniques, and particularly, EVLP. The episode explores: How the study explores the theory that EVLP use may increase transplant volumes Preserving data quality and other study limitations How to work in fields of study that sometimes yield as many questions as answers For the latest studies...
info_outline
Episode 56: The Best Studies of 2024
JHLT: The Podcast
JHLT: The Podcast returns with a year-end recap of 2024. Each Digital Media Editor shares one of their favorite studies from JHLT in 2024 for a quick recap of last year’s excellent science in advanced heart and lung disease. Studies featured: · Kikano, Sandra et al. JHLT May 2024 5(43):745-754 · Rose, Johnie et al. JHLT Aug 2024 8(43):1326-1335. · Schlöglhofer, Thomas et al. JHLT Feb 2024 2(43):251-260. ...
info_outline
Episode 55: Meet the Editors!
JHLT: The Podcast
Happy new year from JHLT: The Podcast! On this episode, the Digital Media Editors are joined by ISHLT Director of Marketing + Communications Jess Burke, CAE, to share a little bit about themselves and their backgrounds. Hear about how each of the JHLT Digital Media Editors got involved in transplantation and a little about each of their research and personal interests. For the latest studies from JHLT, visit , or, if you’re an ISHLT member, access your Journal membership at . Don’t already get the Journal? Join the International Society of Heart and Lung Transplantation...
info_outline
Episode 54: Long-term follow up on the SCHEDULE trial
JHLT: The Podcast
On the second December episode of JHLT: The Podcast, the Digital Media Editors explore another paper from the December issue of JHLT, entitled “.” First author Entela Bollano, MD, PhD, and senior author Niklas Bergh, MD, PhD, both from the Sahlgrenska University Hospital in Sweden, join the podcast to discuss their work. You’ll hear about: Past outcomes of the SCHEDULE trial, including reduced CAV in patients on everolimus over patients on CNIs How this study filled the need for long-term follow up on randomized studies on immunosuppression Limitations of the study, and what additional...
info_outline
Episode 53: Pollution exposure in the first 3 months post-lung transplant
JHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Chung-Wai Chow, MD, PhD, FRCPC, to discuss the paper, “.” Dr. Chow is a transplant pulmonologist and clinician scientist at the University of Toronto, with work focusing on investigating air pollution’s impact on chronic lung diseases and developing improved methods to assess lung function. The episode explores: Measurement methods for home and personal air pollution exposures Specific pollutants like black carbon and their effects on patients after lung transplant Practical advice for mitigating these...
info_outlineReturning for a second study this month, the JHLT Digital Media Editors conduct an internal discussion on the paper, “Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.”
The episode explores:
- The aging PAH population and the new comorbidities that must be considered in research
- How the study augments and expands on recent standards, like the 2022 ESC/ERS guidelines for pulmonary hypertension
- Limitations on the study and opportunities for future research
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Those on lung transplant teams should check the previous episode for a study on how rewarming ischemia time affects lung transplant outcomes.
Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.